Syros Pharmaceuticals, Inc. (0LC7.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 06:30PM BST
| Previous close | 6.02 |
| Open | 6.11 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 6.11 - 6.31 |
| 52-week range | 2.27 - 8.10 |
| Volume | |
| Avg. volume | 817 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.55 |
| Earnings date | 31 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireSyros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
CAMBRIDGE, Mass., July 24, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, July 31, 2024 to report its second quarter 2024 financial results and provide a business update.
ZacksSyros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why
Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, which is being studied for two different cancer indications.
Simply Wall St.Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week
Key Insights Significantly high institutional ownership implies Syros Pharmaceuticals' stock price is sensitive to...
© 2024 Yahoo. All rights reserved.